glp-1 obesity drugs Comparing Ozempic, Wegovy and Other GLP-1 anti-obesity drugs lead to

The microdosing schedule may be prescribed as follows: Weeks 14: 1.0 mg once weekly Weeks 58: 1.5 mg once weekly Weeks 912: 2.0 mg once weekly Week 13 and beyond: Transition to the standard 2.5 mg dose, then proceed with the standard escalation plan

A recent study demonstrated that GLP-1 has a neurotrophic effect and promotes neurotrophic processes in the brain (Mainardi et al., 2015)

The effect of vitamin D supplementation on glycemic control and cardiovascular risk factors in type 2 diabetes: an updated systematic review and meta-analysis of clinical trials

Conclusion In this retrospective case-control study, the use of GLP-1 receptor agonists in patients with type 2 diabetes mellitus was associated with improved ocular surface parameters, including increased tear film stability and tear production, compared to patients on other antidiabetic agents

There are more similarities than differences between the work done in companies and academia, and both are equally valid in my mind

Ultimately, Pfizer discontinued the entire program in April 2025, citing that the risk-benefit profile, including a potential case of drug-induced liver injury (DILI) in a recent study, did not support further development